Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Investing Activities (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash from Investing Activities for 3 consecutive years, with $3646.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 138.75% to $3646.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$60568.0, a 7.73% increase, with the full-year FY2024 number at -$79083.0, up 96.42% from a year prior.
  • Cash from Investing Activities was $3646.0 for Q3 2025 at bioAffinity Technologies, up from -$13427.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $13442.0 in Q4 2023 to a low of -$2.2 million in Q3 2023.
  • A 3-year average of -$213549.9 and a median of -$13427.0 in 2025 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 632.58% in 2024, then surged 138.75% in 2025.
  • bioAffinity Technologies' Cash from Investing Activities stood at $13442.0 in 2023, then tumbled by 100.01% to -$1.0 in 2024, then soared by 364700.0% to $3646.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Cash from Investing Activities are $3646.0 (Q3 2025), -$13427.0 (Q2 2025), and -$50786.0 (Q1 2025).